Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Adnan A Kadi"'
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0214598 (2019)
Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the U
Externí odkaz:
https://doaj.org/article/c99039ff952d4259a13f0f1bf5d2e23c
Autor:
Njood M. Saadan, Wahid U. Ahmed, Adnan A. Kadi, Maha S. Al-Mutairi, Reem I. Al-Wabli, A. F. M. Motiur Rahman
Publikováno v:
ACS Omega, Vol 9, Iss 40, Pp 41944-41967 (2024)
Externí odkaz:
https://doaj.org/article/9b887f31371c448dacec6dfef6180e44
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
IntroductionCEP-37440 was synthesized and supplied by the research and development division of Teva Branded Pharmaceutical Products (West Chester, PA, United States). CEP-37440 represents a newly developed compound that exhibits selectivity inhibitio
Externí odkaz:
https://doaj.org/article/cd01d3edd1a645ceb6ac529f55df8c0d
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0164967 (2016)
In the current work, a rapid, specific, sensitive and validated liquid chromatography tandem mass-spectrometric method was developed for the quantification of ponatinib (PNT) in human plasma and rat liver microsomes (RLMs) with its application to met
Externí odkaz:
https://doaj.org/article/3c55048d83584519b8d43623e8c2d6bc
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e34109- (2024)
The orally given, irreversible, third-generation inhibitor of the epidermal growth factor receptor (EGFR), known as Nazartinib (EGF816), is now undergoing investigation in Phase II clinical trials conducted by Novartis for Non-Small Cell Lung Cancer.
Externí odkaz:
https://doaj.org/article/56f5988244bd42ee8890c17a42fd862a
Publikováno v:
Medicina, Vol 60, Iss 10, p 1626 (2024)
Background and Objectives: Dovitinib (DVB) is a pan-tyrosine kinase inhibitor (TKI) that can be administered orally. In September 2023, the FDA granted Oncoheroes approval to proceed with an Investigational New Drug (IND) application for dovitinib. T
Externí odkaz:
https://doaj.org/article/e33f9546b2814ddaaac014e4801e403e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/a4d524cf84c845ccab1e1a14a1f9fba2
Publikováno v:
Arabian Journal of Chemistry, Vol 12, Iss 8, Pp 2356-2364 (2019)
A series of 8-(substituted)aryloxycaffeine were prepared from 8-bromocaffeine and (substituted)phenols by modified Ullmann reaction. In vitro antibacterial activity, inhibitory activity on topoisomerase II and pharmacological activities were evaluate
Externí odkaz:
https://doaj.org/article/e78139b2965e40e59f9e3fd24025ef1e
Publikováno v:
Crystals; Volume 13; Issue 7; Pages: 1020
This study investigates the crystal structure, physicochemical properties, and pharmacokinetic profile of Ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (EAMT) as a potential therapeutic agent. The crystal structure was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::525e7f025f656a358bc99c5d106e4490
Publikováno v:
Separations; Volume 10; Issue 6; Pages: 353
Dubermatinib (DMB, TP-0903), a benzenesulfonamide, is an inhibitor of the tyrosine kinase AXL, which is a member of the TAM family and can prevent GAS6-mediated activation of AXL in cancer cells. Patients with previously treated chronic lymphocytic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::16f3fc943bc38797a9a0f1eb78d4536d